Ann: Phosphagenics Expands Japanese Option to Oxycodone Patch-POH.AX, page-27

Turps

In the 29 April announcement the two unnamed products are described as “novel TPM® containing pharmaceutical products”. Further on in the announcement it says that “the partnership is broad, involving patch, injectable, and other dosage forms formulated with TPM®”.

As the oxymorphone product is a patch and the propofol an injectable, then it follows that the two remaining products must be the ones referred to as having "other dosage forms".

With respect to the meaning of novel in the context of the announcement, I asked Ross Murdoch if he could clarify whether that was meant to refer to completely novel drugs or novel drugs in the sense that POH had not worked with these drugs before. He confirmed that the latter was the intended meaning. Therefore, the drugs wouldn’t be, for example, diclofenac, tretinoin or lidocaine. However, I'd suppose it doesn’t necessarily rule out the unnamed products being, for example, alternative NSAIDs, acne treatments or topical anaesthetics.